The present invention relates to compounds of formula (I) wherein R1 is a one or two membered heteroaryl group, selected from the group consisting of formula (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) R2 is hydrogen or halogen or R1 and R2 may form together with the carbon atoms to with they are attached the following rings formula (k), (l), (m), (n), (o). R3 is hydrogen, halogen or lower alkyl n is 1 or 2 R4 is phenyl, optionally substituted by one or two substituents, selected from halogen or cyano, or is pyridinyl, optionally substituted by halogen, or is tetrahydropyran, or is -NH-C(O)-phenyl, optionally substituted by halogen R5 is hydrogen or halogen R6 – R13 are phenyl, optionally substituted by halogen: R14 is –NH-C(O)-phenyl, substituted by halogen R15 is hydrogen, lower alkyl substituted by halogen or is halogen R16 is hydrogen or lower alkoxy R17 is pyridinyl, optionally substituted by lower alkoxy or lower alkyl substituted by halogen or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, to all their corresponding enantiomers and/or optical isomers and to all tautomeric forms of compounds of formula I. The compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.La présente invention porte sur des composés de formul
